Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
เดคเตเดฑเด•เตเด•เตเด•
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
โ€”1,093.811,096.521,100.221,091.51โ€”โ€”
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
โ€”608.77608.77612.97608.77โ€”โ€”
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
โ€”1,254.811,253.011,253.871,226.33โ€”โ€”
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
โ€”1,761.111,764.271,766.881,744.71โ€”โ€”
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
โ€”642.58644.87648.48640.18โ€”โ€”
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
โ€”851.13855.66858.75845.56โ€”โ€”
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
โ€”217.98217.98218.65216.88โ€”โ€”
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
โ€”3,211.833,227.213,268.383,226.55โ€”โ€”
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
โ€”948.98948.58957.83941.97โ€”โ€”
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
โ€”1,474.521,479.031,481.041,466.80โ€”โ€”
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
โ€”2,392.122,396.952,421.222,382.32โ€”โ€”
CMVLF:OTCMKTS
Cellectis SA
$3.08
0.00%
(0.00) 1D
เดฎเดพเตผ 30, เดœเดฟเดŽเด‚เดŸเดฟ-4 3:40:10 PM  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CMVLF...
Mkt. cap
เตจเตฎเตฉ.เตซเตฏM
Volume
เตฆ.เตฆเตฆ
52-wk high
$5.04
52-wk low
$1.25
Beta
เตฉ.เตฆเตฎ
Shares outstanding
เตญเตจ.เตฆเตฏM
No. of employees
เตจเตจเตญ
News stories
From sources across the web
Newser
Newser
·
4 เด†เดดเตเดš เดฎเตเดฎเตเดชเต
Is Cellectis (CLLS) Stock Testing Support | Price at $3.44, Up 0.88% - Expert Entry Points
Newser
Newser
·
4 เด†เดดเตเดš เดฎเตเดฎเตเดชเต
Should I Buy Cellectis (CLLS) Stock Now | Price at $3.50, Up 2.64% - Micro Trends
เดชเตเดฐเตŠเดซเตˆเตฝ
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA
CEOเด†เดจเตเดฆเตเดฐเต‡ เดšเต‚เดฒเดฟเด•เตเด•
Employees227
Founded1999
Headquarters-
Sector-
Websitecellectis.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 เดฎเดพเตผ
2025 เดœเต‚เตบ
2025 เดธเต†เดชเตเดฑเตเดฑเด‚
2025 เดกเดฟเดธเด‚
Revenue
12.03M
18.19M
37.16M
12.21M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
21.93M
23.08M
24.07M
24.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.70M
5.08M
5.21M
4.80M
Operating expense
26.21M
27.78M
29.12M
29.56M
Total operating expenses
26.21M
27.78M
29.12M
29.56M
Operating income
-14.18M
-9.59M
8.04M
-17.35M
Other non operating income
2.87M
-282.00K
-7.06M
-8.80M
EBT including unusual items
-18.13M
-23.74M
589.00K
-26.74M
EBT excluding unusual items
-18.13M
-23.74M
589.00K
-26.74M
Income tax expense
-
-
-
-423.00K
Effective tax rate
-
-
-
1.58%
Other operating expenses
-426.00K
-378.00K
-154.00K
320.00K
Net income
-18.13M
-23.74M
589.00K
-26.32M
Net profit margin
-150.71%
-130.46%
1.58%
-215.60%
Earnings per share
-0.17
-0.22
0.02
-0.24
Interest and investment income
-
2.20M
2.31M
2.08M
Interest expense
-
-2.06M
-2.11M
-2.03M
Net interest expenses
-
139.00K
206.00K
44.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.13M
-6.46M
11.16M
-15.33M
Gain or loss from assets sale
1.00K
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer